記事: Tear Trough Filler Risks: 10% Swelling, Sudden Vision Changes
Tear Trough Filler Risks: 10% Swelling, Sudden Vision Changes
Most people who choose tear trough filler experience only mild, temporary bruising or swelling that settles within days to weeks. Uncommon delayed complications and a very small risk of vascular events mean you should still learn the warning signs and choose your clinician carefully. If you ever notice sudden severe pain, skin blanching or a sudden change in vision after treatment, that is a medical emergency.
TL;DR:
- In a review of 52 delayed cases, complications began an average of 16.8 months after injection; swelling accounted for 42.3% and nodules for 25%.
- Ask the clinician to keep each orbit’s filler volume at or below 0.3 mL; higher volumes were linked to more swelling and contour irregularity.
- Hyaluronic acid filler can be dissolved; other fillers carry greater relative risks of nodules and granulomas and lack the same reversal option.
- Before booking, ask how many tear trough procedures the clinician has done, whether hyaluronidase is on site, and how emergencies reach ophthalmology or emergency care.
Table of Contents
- Common short-term side effects and what to expect day-to-day
- Delayed complications: nodules, oedema and skin discolouration
- Severe complications and vascular occlusion: signs and immediate actions
- What raises or lowers your risk before you book
- Questions to ask before choosing a clinician or booking treatment
- How complications are treated and what to expect from recovery
- How to use this guide and where to go next
- Get a clinician’s view before you decide
- FAQ
- Sources
Common short-term side effects and what to expect day-to-day
Short-term reactions are the most frequent outcome of tear trough filler, and for most patients they are mild. In a large retrospective series of 1,452 tear trough applications, 82% of patients reported no complication at all after their first treatment, while 4.3% experienced bruising and 10% experienced swelling, with a median swelling duration of four weeks. The same series recorded contour irregularities in 4.6% of cases and a bluish discolouration known as the Tyndall effect in 3.3%, which happens when filler sits too close to the skin’s surface.
The FDA’s safety guidance on dermal fillers lists bruising, redness, swelling and pain as the common risks across all filler types, reinforcing that these reactions are expected rather than exceptional. Tenderness at the injection site can occur after treatment. Ask your clinician what to expect and when to seek advice.
Most patients notice:
- Mild bruising that resembles a light knock and fades over time.
- Swelling that gradually settles over time.
- Temporary firmness or slight lumpiness that softens as the filler integrates.
Among 1,452 tear trough treatments, 10% of patients experienced swelling, with a median resolution time of four weeks. This matters because a persistent puffy appearance in the first month is a known pattern rather than a sign something has gone wrong, according to the largest published series on the technique.
Simple aftercare helps: ask your clinician whether to avoid vigorous exercise or alcohol after treatment, use cool compresses for swelling, and skip retinoids or active skincare on the treated area for a few days. Ask your clinic when to schedule a routine review, which gives your clinician the chance to assess symmetry and catch any irregularity while it is still easy to correct.
Delayed complications: nodules, oedema and skin discolouration
Not every reaction shows up straight away. Delayed complications after tear trough filler can appear weeks, months or occasionally years after treatment, which is why pre-treatment counselling should cover more than the first fortnight. A systematic review of delayed complications found that swelling was the most common delayed issue, affecting 42.3% of delayed cases, followed by lumps or nodules in 25.0%. Across a pooled set of 52 delayed cases, the average time to onset of any complication was 16.8 months, with some reactions surfacing years after the original injection.
One recognised pattern is malar oedema, a persistent puffiness under the eyes caused by the malar septum trapping fluid above its attachment point in the skin. Hydrophilic or higher-elasticity gels, along with excessive superficial placement, raise this risk, and reported rates of malar oedema after tear trough HA treatment have reached around 11% in some published series.
Key points on delayed reactions:
- Swelling and lumps can develop long after the initial treatment settles, sometimes more than a year later.
- Semi-permanent fillers carry a higher relative risk of nodules and granulomas compared with hyaluronic acid.
- Product choice and injection depth both influence how likely fluid retention becomes over time.
In the same systematic review, hyaluronic acid was the most frequently reported filler type among delayed cases, accounting for 71.2% of them, which reflects how commonly HA is used overall rather than suggesting it carries the highest individual risk.
Severe complications and vascular occlusion: signs and immediate actions
The tear trough sits close to the infraorbital artery and other small vessels with variable anatomy, which makes this region genuinely higher risk than many other facial zones. When filler is accidentally injected into a blood vessel, it can block blood flow to surrounding tissue, a complication known as vascular occlusion. Anatomical reviews of periocular filler complications point to deep, periosteal placement, small aliquots and a lateral-to-medial injection approach as ways to reduce this risk, because the medial tear trough area carries the greatest vascular density.
In a literature review of filler-related vision loss cases, more than half of affected patients experienced severe or irreversible vision loss, and around 19% had a concurrent intracranial embolic event. The American Academy of Ophthalmology’s review notes that the nasal dorsum, forehead and glabella are the most frequently implicated sites, though the tear trough remains a high-risk zone given its complex vascular anatomy. Suspected vascular occlusion needs urgent assessment by a medical professional.
If you or your clinician suspect vascular occlusion, immediate action should include:
- Stopping the injection immediately and alerting the clinician to any sudden, disproportionate pain.
- Looking for skin blanching (a whitening or dusky discolouration) spreading from the injection site.
- Seek immediate emergency medical care for any sudden vision change, severe eye pain or drooping.
- A medical professional should assess suspected vascular occlusion immediately and decide on appropriate treatment.
The FDA also flags vision abnormalities, blindness and stroke among the rare but serious risks associated with unintentional intravascular injection of dermal filler, underlining why clinician skill and rapid access to hyaluronidase are non-negotiable safeguards rather than optional extras.
What raises or lowers your risk before you book
Several factors shape how likely you are to experience a complication, and most of them are knowable in advance. Your own history matters: previous episodes of unexplained facial swelling, autoimmune conditions, or a prior need to have filler dissolved are all worth disclosing at consultation, since they can influence both product choice and technique.
Product selection plays a comparable role. Hyaluronic acid fillers can be dissolved quickly if problems arise, while semi-permanent fillers carry a higher relative risk of nodules and granulomas and cannot be reversed in the same way. Hydrophilic or highly cohesive HA gels are more likely to contribute to malar oedema, so a clinician who tailors product choice to the tear trough’s thin, delicate tissue is working in your favour.
Technique-level factors that lower risk include:
- Limiting injection volume to around 0.3 mL per orbit, a threshold associated with lower rates of swelling and contour irregularity in a large published series.
- Using a blunt cannula rather than a sharp needle where appropriate, since this generally reduces vascular trauma.
- Confirming the clinic keeps hyaluronidase on-site and has a clear referral pathway to ophthalmology or emergency care.
Pro Tip: Ask your clinician directly what their injection volume limit is for the tear trough before treatment begins, not after.
Injection volumes exceeding 0.3 mL per orbit were significantly associated with increased rates of both edema and contour irregularity in the largest published series on this technique, which makes volume one of the few variables you can discuss and agree in advance.
Questions to ask before choosing a clinician or booking treatment
A short checklist at consultation can meaningfully reduce your risk, since it filters for experience and preparedness rather than price or convenience alone.
- Ask how many tear trough procedures the clinician has personally performed, not just injectables in general.
- Ask them to describe how they have managed complications in the past, including any vascular events.
- Confirm which product they plan to use, the expected volume per orbit, and their conservative upper limit for that area.
- Ask whether hyaluronidase is kept on-site and what the emergency referral pathway looks like if a problem develops.
- Ask whether they use a cannula technique for this area and request before-and-after examples specific to tear trough treatment.
A clinician who answers these questions readily and specifically, rather than generically, is usually one who has thought carefully about this particular anatomical zone.
How complications are treated and what to expect from recovery
Most common side effects need no active treatment beyond time and simple aftercare, but when intervention is needed, the approach depends on what has gone wrong. A clinician can assess unwanted lumps, overcorrection or suspected vascular occlusion involving hyaluronic acid filler and discuss appropriate treatment. Hyaluronidase was used to dissolve filler in 1.9% of cases in the largest published tear trough series. Dissolving may improve the appearance, but results and recovery vary, and full resolution of swelling can take longer.
Treatment approaches vary by complication type:
- Inflammatory nodules or suspected infection may require a course of antibiotics or steroids, chosen based on clinical assessment.
- Persistent or treatment-resistant lumps occasionally need surgical removal when dissolving does not fully resolve them.
- Vascular occlusion requires urgent hyaluronidase alongside close monitoring, and severe cases may involve specialist ophthalmology input.
The prognosis for the overwhelming majority of patients is reassuring: bruising and swelling resolve on their own, and some delayed nodules may be treated with dissolving, depending on clinical assessment. Severe vascular events are rare, but when they do occur, some sequelae, particularly vision changes, may be permanent if treatment is delayed. That asymmetry, common issues resolve fully while rare ones can be serious, is exactly why timing and clinician responsiveness matter so much.
How to use this guide and where to go next
Knowing the data changes how you approach a consultation. We think the most useful shift you can make is treating your first conversation with a clinician as a safety interview, not a sales pitch, asking the direct questions this guide outlines before ever discussing product or price. Filler is not the only way to address hollowing or discolouration under the eyes, and a clinician who is willing to discuss alternatives alongside injectables is usually one worth trusting with a needle near your eye.
— Jess
Get a clinician’s view before you decide
Reading about risk is useful, but a personalised assessment tells you whether tear trough filler suits your anatomy and history at all. Our online skin consultation connects you with an expert clinician who can review your concerns, discuss product and volume options suited to you, and talk through what a sensible management plan looks like if anything needs attention later.
- A dedicated one-to-one review of your under-eye concerns and suitability for treatment.
- Clear guidance on product choice, expected volumes and realistic timelines.
- A chance to ask about safety measures, including how complications would be managed, before you commit to anything.
If in-clinic treatment feels right afterwards, our clinic services in London and Athens include Profhilo, microneedling, HIFU and polynucleotides, giving you options beyond filler alone.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
How risky is tear trough filler?
For most people, tear trough filler is low risk, with bruising, swelling and mild contour irregularity being the most likely outcomes. Severe complications such as vascular occlusion or vision changes are rare but possible, which is why choosing an experienced injector and knowing the warning signs both matter.
What is the riskiest place for fillers?
The tear trough and surrounding midface are considered among the higher-risk zones for filler because of the infraorbital artery and variable vessel anatomy close to the orbital rim. Other areas, including the nasal dorsum, forehead and glabella, have also been linked to serious vascular events in reported case reviews.
Is filler in the tear trough worth it?
Many people find tear trough filler improves hollowing and shadowing under the eyes with a relatively quick, low-downtime procedure. Whether it is worth it for you depends on your anatomy, medical history and comfort with the small risk of delayed or vascular complications, which is best discussed during a clinician consultation.
Who shouldn’t get tear trough filler?
People with a history of unexplained facial swelling, certain autoimmune conditions, or previous complications requiring filler dissolving should discuss these carefully with a clinician before proceeding. A thorough consultation helps determine whether tear trough filler is appropriate or whether an alternative approach makes more sense for your situation.
Sources
- Tear Trough Filler Using the Three-point Tangent Technique: Lessons from 1452 Tear Trough Applications - PMC
- Intravascular Injection of Soft-Tissue Fillers Can Have Severe Visual Consequences - American Academy of Ophthalmology
- Dermal Fillers (Soft Tissue Fillers) | FDA
- Delayed Complications following Dermal Filler for Tear …
